This study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT),
safety and pharmacokinetics (PK) profile of a single agent CKD-581 injection in patients with
Lymphoma failed to standard therapy. The usefulness of the this regimen is evaluated by
response rate, progression free survival.